LinkedIn
WebsiteIntroduction
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical development company focused on neuroscience indications. The company holds exclusive U.S., Canadian, and Mexican rights to two pipeline assets: Ketamir-2, a novel oral ketamine analog targeting neuropathic pain, treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder; and MIRA-55, an oral cannabis analog under evaluation for anxiety and cognitive decline often associated with early-stage dementia. On October 16, 2025, MIRA shares closed at $2.33, reflecting a 76.52% intraday increase on trading volume of 16,388,406 shares.
| Ticker | Exchange | Closing Price (10/16/2025) | Change (%) | Volume |
|---|---|---|---|---|
| MIRA | NASDAQ | $2.33 | +76.52 | 16,388,406 |
Corporate Structure
MIRA Pharmaceuticals operates under a corporate governance framework that includes an independent board of directors supported by audit and ethics committees. Shareholders and stakeholders can communicate anonymously regarding accounting or auditing concerns via [email protected]. The company has not publicly disclosed its total employee count; however, it has teams across chemistry, preclinical studies, and regulatory affairs to support its clinical-stage pipeline.
Neuroscience by Milad Fakurian
Recent Developments and News
⢠Acquisition of SKNY Pharmaceuticals: In September 2025, MIRA completed the acquisition of SKNY-1, a next-generation oral therapy. Preclinical data indicated up to 30% weight reduction and reversal of nicotine cravings.
⢠SEC Filings: On October 15, 2025, MIRA filed a Form 8-K under Item 8.01 reporting unspecified corporate updates. Earlier filings on September 30, 2025 (Items 1.01, 2.01, 3.02, 8.01, 9.01) and September 22, 2025 (Item 8.01) covered routine matters such as board communications and accounting controls.
⢠Pipeline Milestones: An initial IND submission for Ketamir-2 is positioned for Q4 2024, while MIRA-55 development is targeted for the first half of 2025.
⢠Scientific Review: The U.S. DEAâs scientific assessment determined that neither Ketamir-2 nor MIRA-55 meets the criteria for controlled substances under the Controlled Substances Act.
Financial and Strategic Aspects
While detailed financial results for Q2 2024 (quarter ended June 30, 2024) were released, specific revenue and expense figures have not been publicly summarized. The share price increase of 76.52% and elevated trading volume on October 16, 2025, may be linked to investor response following the SKNY-1 acquisition and upcoming IND milestones. MIRAâs focus on novel analogs in pain, depression, and cognitive disorders aims to address markets with high unmet needs while leveraging regulatory determinations regarding the non-controlled status of its candidates.
Market Position and Industry Context
MIRA competes in a crowded neuroscience R&D landscape, where companies are pursuing ketamine derivatives and cannabinoid-based therapies. Its dual-program approachâaddressing both psychiatric and neurologic indicationsâprovides diversification across central nervous system disorders. The non-controlled status of its lead assets may streamline clinical development compared to controlled compounds. Partnerships, potential out-licensing, and successful IND clearances will be important for advancing each program through Phase I/II studies and navigating competition from larger pharmaceutical companies.
tl;dr
On October 16, 2025, MIRA Pharmaceuticalsâ shares increased by 76.52% to $2.33 on high volume following the September acquisition of SKNY-1, which preclinical data indicated could achieve up to 30% weight reduction and nicotine-craving reversal. A Form 8-K filed on October 15 documented corporate updates, while IND submissions for Ketamir-2 and MIRA-55 are anticipated between Q4 2024 and mid-2025. Market attention is now focused on regulatory feedback regarding these IND submissions and the integration progress of the newly acquired SKNY-1 program.
